NCT05614063Phase 3Completed

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Study sponsor: Xenon Pharmaceuticals Inc. · XENE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-01-12Actual
Enrollment · participants380Actual
Source updated2026-05-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 360 participants (planned). After: 380 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2025. After: 12 Jan 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview